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ABSTRACT

Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the
implementation or manipulation of triacylglycerol synthase
like polypeptides or polynucleotides encoding the same. The
methods are useful in identifying agents active against TB
infection.
1 Claim, 7 Drawing Sheets
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TARGETING OF TRIACYLCLYCEROL
SYNTHASE GENE FOR TUBERCULOSIS
TREATMENT

ti on is infected with the latent microorganism and nearly two
million deaths occur annually (Dye, C., Scheele, S., Dolin, P.,
Pathania, V., and Raviglione M. C. (1999) JAMA. 282, 677686, WHO Report. (2005) WHO/HTM/TB/2005). Individuals carrying a latent infection are estimated to harbor a 2-23%
lifetime risk of reactivation (Zahrt, T. C. (2003). Microbes
Infect. 5, 159-167).
If an individual has TB disease, i.e., has active TB, the
individual typically is administered a combination of several
drugs. It is very important, however, that the individual continue a correct treatment regimen for the full length of the
treatment. If the drugs are taken incorrectly, or stopped, the
individual can suffer a relapse and will be able to infect others
with TB. When an individual becomes sick with TB a second
time, the TB infection may be more difficult to treat because
the TB bacteria have become drug resistant, i.e., TB bacteria
in the body are unaffected by some drugs used to treat TB.
Multidrug-resistant tuberculosis (MDR TB) is a very dangerous form of tuberculosis. In particular, some TB bacteria
become resistant to the effects of various anti-TB drugs, and
these resistant TB bacteria then can cause TB disease. Like
regular TB, MDR TB can be spread to others.
To avoid drug resistance in the treatment of TB, a four-drug
regimen, i.e., isoniazid, rifampin, pyrazinamide, and streptomycin, is administered to TB patients. Aminoglycosides,
such as streptomycin, are important anti-TB agents, but their
utility is restricted by the requirement of parenteral administration, which is inconvenient and leads to poor patient compliance. It is theorized that poor patient compliance also can
lead to the development of drug resistance, and it appears that
the frequency of streptomycin resistance among anti-TB
drugs is surpassed only by isoniazid.
In view of the above, an urgent need exists for new anti-TB
agents useful in an effective treatment regimen for both the
active and latent TB, and that effectively treat TB caused by
multidrug resistant (MDR) strains of bacteria. Therefore, it
would be advantageous to provide compounds and compositions for administration to an individual in the treatment of
tuberculosis.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 11/561,477; filed Nov. 20, 2006, now U.S. Pat.
No. 7,579,012, which is related to U.S. Provisional Patent No.
60/748,283 filed Dec. 7, 2005, which is incorporated herein
by reference. Priority is claimed under 35 USC §§120, 119.
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This invention was made through support from the NIH,
GrantNos.AI46582 andAI35272. The government may have
certain rights in this invention.
BACKGROUND
Tuberculosis (TB) has been a major health problem for
most of recorded history and Mycobacterium tuberculosis
remains one of the world's most significant pathogens.
Responsible for millions of new cases of tuberculosis annually (see e.g. Pablo-Mendez et al., (1998) New Engl. J. Med.
338, 1641-1649), it is the leading cause of death from a single
infectious agent. While the incidence of the disease declined
in parallel with advancing standards ofliving since at least the
mid-nineteenth century, in spite of the efforts of numerous
health organizations worldwide, the eradication of tuberculosis has never been achieved, nor is imminent.
TB is acquired by the respiratory route; actively infected
individuals spread this infection efficiently by coughing or
sneezing "droplet nuclei" which contain viable bacilli. Overcrowded living conditions and shared air spaces are especially conducive to the spread of TB, underlying the increase
in instances that have been observed in the U.S. in prison
inmates and among the homeless in larger cities.
Medical experts estimate that about 10 million Americans
are infected with TB bacteria, and about 10 percent of these
people will develop active TB in their lifetime. However, TB
is an increasing worldwide problem, especially in Africa. It is
estimated that, worldwide, about one billion people will
become newly infected, over 150 million people will contract
active TB, and 36 million people will die between now and
2020 unless TB control is improved.
The emergence of multi-drug resistant strains of Myca bacterium tuberculosis poses serious threats to the control ofthis
disease due to the complex nature of second-line drug treatment (WHO Report. (2004) WHO/HTM/TB/2004.343).
Upon infection the bacterium goes through an initial replicative phase inside the alveolar macrophages after which it
enters a non-replicative, drug-resistant state of dormancy.
This state of dormancy is probably induced by the environmental stress exerted upon the pathogen by the host's immune
response. The bacterium is able to survive in this dormant
state for decades until the host's immune system is weakened
when it reactivates and causes the infectious disease (Dannenberg, Jr., A. M., and Rook G. A. W. (1994) In Tuberculosis: Pathogenesis, Protection and Control, Bloom, B. R.,
(Ed.) American Society of Microbiology, Washington D.C.).
The current anti-mycobacterial drugs are able to kill only the
actively replicating mycobacteria and do not clear the latent
bacteria from the host (Honer zu Bentrup, K., and Russell D.
G. (2001) Trends Microbial. 9, 597-605). Thus latency is a
major problem in TB control. One-third of the world popula-
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FIG.1. Generation of a tgsl mutant of M. tuberculosis. (A)
Schematic representation of the disruption construct fortgsl.
Hatched and checkered regions represent the regions used to
make disruption construct. The checkered segment was
replaced with hyg gene cassette (black box). Primers pairs
E/Hl, H2/F and AF/AR were used for PCR analysis of
homologous recombination as described in text. (B) Southern
blot hybridization of the wild type (WT) and three mutant
clones (Ml, M2 andM3). (C) RT-PCRanalysis showingtgsl
transcript in wild type (WT) and tgsl-complemented strain
(C-MUT), but not in tgsl mutant (MUT).
FIG. 2. Dichromate/sulphuric acid charring oflipids showing triacylglycerol (TG) accumulation in M. tuberculosis
under hypoxia. At each time point total lipids were extracted
from wild typeM. tuberculosis (WT) and tgsl mutant (MUT)
(A) and after 6 h of incubation with 50 IM oleic acid-0.5%
BSA (B). In each case same proportion of lipids were separated by TLC using n-hexane:diethyl ether (9: 1, v/v). The
intensity of the TG band determined in arbitrary units by
Alphaimager 2200 Gel Doc system is shown on top of each
panel.
FIG. 3. GC analysis of fatty acids in TG from M. tuberculosis cells after 16 days under hypoxia. Methyl esters of fatty
acid were prepared from TG recovered from TLC plates from
the wild type, tgs 1 mutant and complemented tgsl mutant.

US 7,993,658 B2
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Top, middle and bottom panel represent wild type (WT), tgs 1
mutant and tgsl-complemented strain, respectively. Retention times of nfatty acids are indicated on top.
FIG. 4. TG accumulation in M. tuberculosis (WT), tgsl
mutant (MUT) and complemented tgsl mutant (C-MUT) 5
after 16 days under hypoxia. Same proportion oflipids were
separated by TLC using n-hexane:diethyl ether (9: 1, v/v) and
lipids were visualized by dichromate/sulfuric acid charring.
Charred TLC chromatogram is shown from a typical experiment and the intensity of the TG band was determined in 10
arbitrary units by theAlphaimager 2200 Gel Doc system. The
values are given as ±SEM of three independent measurements.
FIG. 5. Effects ofacyl chain-length and pH on TG synthesis by recombinant TGSl. A, total cell lysate of E. coli 15
expressing TGSl was assayed for TGS activity using C 26 ,0 CoA (•) andC 18 , 1 -CoA (D). B, Effect of pH on TGS activity
Assays were done in 0.1 M citrate-phosphate buffer pH 3.5/
4.515.516.5 (_..)or 0.1 M Tris-HCl pH 7.0/7.5/8.0/9.0 (D).
FIG. 6. Dichromate-sulphuric acid charring oflipids show- 20
ing TG accumulation in M. tuberculosis grown under stress
conditions. Total lipids extracted from wild type (WT), tgsl
mutant (MUT) and complemented tgsl mutant (C-MUT)
under A, low pH growth, B, static growth and C, upon NO
treatment. In each case same proportion oflipids were sepa- 25
rated by TLC usingn-hexane:diethyl ether (9: 1, v/v). Charred
TLC chromatograms are shown from a typical experiment
and the intensity of the TG band was determined in arbitrary
units by the Alphalmager 2200 Gel Doc system. The values
30
are given as ±SEM of three independent measurements.
FIG. 7. Induction oftgs genes inM. tuberculosis strains by
NO treatment. Transcript levels were measured by semiquantitative RT-PCR and expressed as a fraction of the 23S rRNA
transcript level. WT, wild type; MUT, tgsl mutant; C-MUT,
35
tgs I-complemented strain.
DETAILED DESCRIPTION
The ability of Mycobacterium tuberculosis to go into a
latent/dormant state and survive under such conditions for
decades make TB control extremely difficult. Developing
drugs targeted at the ability of the pathogen to survive under
such latent conditions for long periods is one way to fight
against latent TB. The invention is based, in part, on the
inventors discovery of a novel TB gene (Rv3130c) encoding
an enzyme required for Mycobacterium tuberculosis to store
energy in order to enter and survive the dormancy (or latent)
period. The gene sequence is provided as SEQ ID NO: 1. The
inventors have discovered that triacylglycerol (TG) can be
used as an energy source by M. tuberculosis during the dormancy period, thus its synthesis could be an ideal drug target
against latent TB. SEQ ID NO: 2 shows one example of a M.
tuberculosis TG storage (MTTGS) polypeptide. Polypeptides useful in accordance with the teachings herein is further
described herein. MTTGS polynucleotides and polypeptides
as described herein may be implemented to identify compounds to treat TB.
Thus, according to one embodiment, the invention pertains
to a method of screening for therapeutic agents useful in the
treatment of Mycobacterium tuberculosis infection in a mammal comprising the steps of i) contacting a test compound
with a MTTGS polypeptide, ii) detecting binding of said test
compound to said MTTGS polypeptide.
Another embodiment of the subject invention pertains to a
method of screening for therapeutic agents useful in the treatment of Mycobacterium tuberculosis infection in a mammal
comprising the steps of i) determining the activity of a
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MTTGS polypeptide at a certain concentration of a test compound or in the absence of said test compound, ii) determining the activity of said polypeptide at a different concentration of said test compound.
1. Screening Methods
The invention provides assays for screening test compounds which bind to or modulate the activity of an
MTTGS polypeptide or bind to and inhibit or affect
expression of an MTTGS polynucleotide. A test compound preferably binds to an MTTGS polypeptide.
More preferably, a test compound decreases or increases
MTTGS activity by at least about 10, preferably about
50, more preferably about 75, 90, or 100%relativeto the
absence of the test compound.
1.1. Test Compounds
Test compounds relate to agents that potentially have therapeutic activity, i.e., bind to or modulate the activity of an
MTTGS polypeptide or bind to or affect expression of an
MTTGS polynucleotide. Test compounds can be pharmacologic agents already known in the art or can be
compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be isolated
from microorganisms, animals, or plants, and can be
produced recombinantly, or synthesized by chemical
methods known in the art. If desired, test compounds can
be obtained using any of the numerous combinatorial
library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel
solid phase or solution phase libraries, synthetic library
methods requiring deconvolution, the "one-bead onecompound" library method, and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide
libraries, while the other four approaches are applicable
to polypeptide, non-peptide oligomer, or small molecule
libraries of compounds. See Lam, Anticancer Drug Des.
12, 145, 1997.
Methods for the synthesis of molecular libraries are well
known in the art (see, for example, DeWitt et al., Proc.
Natl. Acad. Sci. U.S.A. 90, 6909, 1993; Erb et al. Proc.
Natl.Acad. Sci. U.S.A. 91, 11422, 1994; Zuckermannet
al., J. Med. Chem. 37, 2678, 1994; Cho et al., Science
261, 1303, 1993; Carell et al., Angew. Chem. Int. Ed.
Engl. 33, 2059, 1994; Carell et al., Angew. Chem. Int.
Ed. Engl. 33, 2061; Gallop et al., J. Med. Chem. 37,
1233, 1994).
1.2. High Throughput Screening
Test compounds can be screened for the ability to bind to and
inhibit MTTGS polypeptides or polynucleotides or to affect
MTTGS activity or MTTGS gene expression using high
throughput screening. Using high throughput screening,
many discrete compounds can be tested in parallel so that
large numbers of test compounds can be quickly screened.
The most widely established techniques utilize 96-well
microtiter plates. The wells of the microtiter plates typically
require assay volumes that range from 50 to 500 µ!.In addition to the plates, many instruments, materials, pipettors,
robotics, plate washers, and plate readers are commercially
available to fit the 96-well format. Alternatively, "free format
assays," or assays that have no physical barrier between
samples, can be used.
1.3. Binding Assays
For binding assays, the test compound is preferably, but not
necessarily, a small molecule which binds to and occupies, for
example, the active site of the MTTGS polypeptide, such that
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normal biological activity is prevented. Examples of such
small molecules include, but are not limited to, small peptides
or peptide-like molecules.
In binding assays, either the test compound or the MTTGS
polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label,
such as horseradish peroxidase, alkaline phosphatase, or
luciferase. Detection of a test compound which is bound to
the MTTGS polypeptide can then be accomplished, for
example, by direct counting ofradioemmission, by scintillati on counting, or by determining conversion of an appropriate
substrate to a detectable product.
Those skilled in the art equipped with teachings herein will
appreciate that there are multiple conventional methods of
detecting binding of a test compound. For example, binding
of a test compound to a MTTGS polypeptide can be determined without labeling either of the interactants. A microphysiometer can be used to detect binding of a test compound
with an MTTGS polypeptide. A microphysiometer (e.g.,
CYTOSENSOR™) is an analytical instrument that measures
the rate at which a cell acidifies its environment using a
light-addressable potentiometric sensor (LAPS). Changes in
this acidification rate can be used as an indicator of the interaction between a test compound and an MTTGS polypeptide
(McConnell et al., Science 257, 1906-1912, 1992).
In another alternative example, determining the ability of a
test compound to bind to an MTTGS polypeptide can be
accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky,
Anal Chem. 63, 2338-2345, 1991, and Szabo et al., Curr.
Opin. Struct. Biol. 5, 699-705, 1995). BIA is a technology for
studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore™). Changes in the
optical phenomenon surface plasmon resonance (SPR) can be
used as an indication ofreal-time reactions between biological molecules.
In yet another aspect of the invention, an MTTGS polypeptide can be used as a "bait protein" in a two-hybrid assay or
three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos
et al., Cell 72, 223-232, 1993; Madura et al., J. Biol. Chem.
268, 12046-12054, 1993; Bartel et al., BioTechniques 14,
920924, 1993; Iwabuchi et al., Oncogene 8, 1693-1696,
1993; and Brent W094/10300), to identify other proteins
which bind to or interact with the MTTGS polypeptide and
modulate its activity.
In many screening embodiments, it may be desirable to
immobilize either the MTTGS polypeptide (or polynucleotide) or the test compound to facilitate separation of bound
from unbound forms of one or both of the interactants, as well
as to accommodate automation of the assay. Thus, either the
MTTGS polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports
include, but are not limited to, glass or plastic slides, tissue
culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex,
polystyrene, or glass beads). Any method known in the art can
be used to attach the MTTGS polypeptide (orpolynucleotide)
or test compound to a solid support, including use of covalent
and non-covalent linkages, passive absorption, or pairs of
binding moieties attached respectively to the polypeptide (or
polynucleotide) or test compound and the solid support. Test
compounds are preferably bound to the solid support in an
array, so that the location of individual test compounds can be
tracked. Binding of a test compound to a MTTGS polypeptide
(or polynucleotide) can be accomplished in any vessel suit-

able for containing the reactants. Examples of such vessels
include microtiter plates, test tubes, and microcentrifuge
tubes.
In a specific embodiment, the MTTGS polypeptide may be
a fusion protein comprising a domain that allows the MTTGS
polypeptide to be bound to a solid support. For example,
glutathione S-transferase fusion proteins can be adsorbed
onto glutathione sepharose beads (Sigma Chemical, St.
Louis, Mo.) or glutathione derivatized microtiter plates,
which are then combined with the test compound or the test
compound and the nonadsorbed MTTGS polypeptide; the
mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and
pH). Following incubation, the beads ormicrotiterplate wells
are washed to remove any unbound components. Binding of
the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can
be dissociated from the solid support before binding is determined.
Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening
assays of the invention. For example, either a MTTGS
polypeptide (or polynucleotide) or a test compound can be
immobilized utilizing conjugation of biotin and streptavidin.
Biotinylated MTTGS polypeptides (or polynucleotides) or
test compounds can be prepared from biotinNHS (Nhydroxysuccinimide) using techniques well known in the art (e.g.,
biotinylation kit, Pierce Chemicals, Rockford, Ill.) and
immobilized in the wells of streptavidin-coated 96 well plates
(Pierce Chemical). Alternatively, antibodies which specifically bind to a MTTGS polypeptide, polynucleotide, or a test
compound, but which do not interfere with a desired binding
site, such as the active site of the MTTGS polypeptide, can be
derivatized to the wells of the plate. Unbound target or protein
can be trapped in the wells by antibody conjugation.
Methods for detecting such complexes, in addition to those
described above for the GST-immobilized complexes,
include immunodetection of complexes using antibodies
which specifically bind to the MTTGS polypeptide or test
compound, enzyme-linked assays which rely on detecting an
activity of the MTTGS polypeptide, and SDS gel electrophoresis under non-reducing conditions.
Screening for test compounds which bind to a MTTGS
polypeptide or polynucleotide also can be carried out in an
intact cell. Any cell which comprises a MTTGS polypeptide
or polynucleotide can be used in a cell-based assay system. A
MTTGS polynucleotide can be naturally occurring in the cell
or can be introduced using techniques such as those described
above. Binding of the test compound to a MTTGS polypeptide or polynucleotide is determined as described above.
1.4. Enzyme Assays
Test compounds can be tested for the ability to increase or
decrease the TGS activity of a MTTGS polypeptide. TGS
activity can be measured, for example, by adapting techniques such as that described in U.S. Pat. No. 4,529,693 (see
Example 2). Enzyme assays can be carried out after contacting either a purified MTTGS polypeptide, a cell membrane
preparation, or an intact cell with a test compound. A test
compound which decreases TGS activity of a MTTGS
polypeptide by at least about 10, preferably about 50, more
preferably about 75, 90, or 100% is identified as a potential
therapeutic agent for decreasing MTTGS activity. A test compound which increases TGS MTTGS polypeptide by at least
about 10, preferably about 50, more preferably about 75, 90,
or 100% is identified as a potential therapeutic agent for
increasing TGS activity.
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1.5. Gene Expression
means. Pharmaceutical compositions for oral administration
In another embodiment, test compounds which increase or
can be formulated using pharmaceutically acceptable carriers
decrease MTTGS gene expression are identified. An MTTGS
well known in the art in dosages suitable for oral administrapolynucleotide is contacted with a test compound, and the
tion. Such carriers enable the pharmaceutical compositions to
expression of an RNA or polypeptide product of the MTTGS
be formulated as tablets, pills, dragees, capsules, liquids, gels,
polynucleotide is determined. The level of expression of
syrups, slurries, suspensions, and the like, for ingestion by the
appropriate mRNA or polypeptide in the presence of the test
patient.
compound is compared to the level of expression of mRNA or
Further details on techniques for formulation and adminpolypeptide in the absence of the test compound. The test
istration can be found in the latest edition ofREMINGTON'S
compound can then be identified as a modulator of expression 10
PHARMACEUTICAL SCIENCES (Maack Publishing Co.,
based on this comparison. For example, when expression of
Easton, Pa., which is incorporated herein by reference). After
mRNA or polypeptide is greater in the presence of the test
pharmaceutical compositions have been prepared, they can
compound than in its absence, the test compound is identified
be placed in an appropriate container and labeled for treatas a stimulator or enhancer of the mRNA or polypeptide
expression. Alternatively, when expression of the mRNA or 15 ment of an indicated condition. Such labeling would include
amount, frequency, and method of administration.
polypeptide is less in the presence of the test compound than
This invention further pertains to the use of novel agents
in its absence, the test compound is identified as an inhibitor
identified
by the screening assays described above. Accordof the mRNA or polypeptide expression.
ingly, it is within the scope of this invention to use a theraThe level of MTTGS mRNA or polypeptide expression in
the cells can be determined by methods well known in the art 20 peutic agent identified as described herein in an appropriate
animal model. For example, an agent identified as described
for detecting mRNA or polypeptide. Either qualitative or
herein (for example, but not limited to, a modulating agent, an
quantitative methods can be used. The presence of polypeptide products of an MTTGS polynucleotide can be deterantisense nucleic acid molecule, a specific antibody,
mined, for example, using a variety of techniques known in
ribozyme, or a MTTGS polypeptide binding molecule) can be
the art, including immunochemical methods such as radioim- 25 used in an animal model to determine the efficacy, toxicity, or
munoassay, Western blotting, and immunohistochemistry.
side effects of treatment with such an agent. Furthermore, this
Alternatively, polypeptide synthesis can be determined in
invention pertains to uses of novel agents identified by the
vivo, in a cell culture, or in an in vitro translation system by
above described screening assays for treatments as described
detecting incorporation oflabeled amino acids into a MTTGS
herein.
polypeptide.
30
Those skilled in the art will appreciate that numerous delivSuch screening can be carried out either in a cell-free assay
ery mechanisms are available for delivering a therapeutic
system or in an intact cell. Any cell which expresses a
agent to an area of need. By way of example, the agent may be
MTTGS polynucleotide can be used in a cell-based assay
delivered using a liposome as the delivery vehicle. Preferably,
system. The MTTGS polynucleotide can be naturally occurthe
liposome is stable in the animal into which it has been
ring in the cell or can be introduced using techniques such as 35
administered for at least about 30 minutes, more preferably
those described above. Either a primary culture or an estabfor at least about 1 hour, and even more preferably for at least
lished cell line, such as CHO or human embryonic kidney 293
about 24 hours. A liposome comprises a lipid composition
cells, can be used.
that is capable of targeting a reagent, particularly a polynucle2. Pharmaceutical Compositions
The invention also pertains to pharmaceutical composi- 40 otide, to a particular site in an animal, such as a human. A
liposome useful in the present invention comprises a lipid
tions comprising one or more therapeutic agents that are
composition that is capable of fusing with the plasma memidentified by screening methods that utilize MTTGS polypepbrane of the targeted cell to deliver its contents to the cell.
tides and/or polynucleotides. Therapeutic agent(s) can be
administered to a patient to achieve a therapeutic effect, i.e.
Preferably, the transfection efficiency of a liposome is about
useful in treatment of TB. Pharmaceutical compositions of 45 0.5 µg of DNA per 16 nmole ofliposome delivered to about
the invention can comprise, for example, therapeutic agents
106 cells, more preferably about 1.0 µg of DNA per 16 nmole
identified by a screening method embodiment described
ofliposome delivered to about 106 cells, and even more prefherein, which are identified by their ability to bind to or affect
erably about 2.0 µg of DNA per 16 nmol of liposome delivactivity of MTTGS polypeptides, or bind to and/or affect
ered to about 10 6 cells. Preferably, a liposome is between
expression MTTGS polynucleotides. The compositions can 50 about 100 and 500 nm, more preferably between about 150
be administered alone or in combination with at least one
and 450 nm, and even more preferably between about 200 and
400 nm in diameter.
other agent, such as stabilizing compound, which can be
administered in any sterile, biocompatible pharmaceutical
Suitable liposomes for use in the present invention include
carrier, including, but not limited to, saline, buffered saline,
those liposomes standardly used in, for example, gene delivdextrose, and water. The compositions can be administered to 55 ery methods known to those of skill in the art. More preferred
a patient alone, or in combination with other agents, drugs or
liposomes include liposomes having a polycationic lipid
hormones.
composition and/or liposomes having a cholesterol backbone
In addition to the active ingredients, these pharmaceutical
conjugated to polyethylene glycol. Optionally, a liposome
compositions can contain suitable pharmaceutically acceptcomprises a compound capable of targeting the liposome to a
able carriers comprising excipients and auxiliaries which 60 particular cell type, such as a cell-specific ligand exposed on
facilitate processing of the active compounds into preparathe outer surface of the liposome.
Complexing a liposome with a reagent such as an antisense
tions which can be used pharmaceutically. Pharmaceutical
oligonucleotide or ribozyme can be achieved using methods
compositions of the invention can be administered by any
number of routes including, but not limited to, oral, intravewhich are standard in the art (see, for example, U.S. Pat. No.
nous, intramuscular, intra-arterial, intramedullary, intrathe- 65 5,705,151). Preferably, from about 0.1 µg to about 10 µg of
cal, intraventricular, transdermal, subcutaneous, intraperitopolynucleotide is combined with about 8 nmol ofliposomes,
neal, intranasal, parenteral, topical, sublingual, or rectal
more preferably from about 0.5 µg to about 5 µg of polynucle-
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otides are combined with about 8 nmol liposomes, and even
more preferably about 1.0 µg of polynucleotides is combined
with about 8 nmol liposomes.
In another embodiment, antibodies can be delivered to
specific tissues in vivo using receptor-mediated targeted
delivery. Receptor-mediated DNA delivery techniques are
taught in, for example, Findeis et al. Trends in Biotechnol. 11,
202-05 (1993); Chiou et al., GENE THERAPEUTICS:
METHODS AND APPLICATIONS OF DIRECT GENE
TRANSFER (J. A. Wolff, ed.) (1994); Wu & Wu, J. Biol.
Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269,
542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87,
3655-59 (1990); Wu et al., J. Biol. Chem. 266, 338-42 (1991).
2.1 Determination of a Therapeutically Effective Dose
The determination of a therapeutically effective dose of therapeutic agents identified by a screening method herein is well
within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient
which attenuates or eliminates TB infection contrasted to TB
infection or attenuation that occurs in the absence of the
therapeutically effective dose.
Therapeutic efficacy and toxicity, e.g., ED 50 (the dose
therapeutically effective in 50% of the population) and LD 50
(the dose lethal to 50% of the population), can be determined
by standard pharmaceutical procedures in cell cultures or
experimental animals. The dose ratio of toxic to therapeutic
effects is the therapeutic index, and it can be expressed as the
ratio, LD 50/ED 50 .
The exact dosage will be determined by the practitioner, in
light of factors related to the subject that requires treatment.
Dosage and administration are adjusted to provide sufficient
levels of the active ingredient or to maintain the desired effect.
Factors which can be taken into account include the severity
of the disease state, general health of the subject, age, weight,
and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical
compositions can be administered every 3 to 4 days, every
week, or once every two weeks depending on the half-life and
clearance rate of the particular formulation.
Normal dosage amounts can vary from 0.1 to 100,000
micrograms, up to a total dose of about 1 g, depending upon
the route of administration. Guidance as to particular dosages
and methods of delivery is provided in the literature and
generally available to practitioners in the art. Those skilled in
the art will employ different formulations for nucleotides than
for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells,
conditions, locations, etc.
Preferably, an therapeutic agent reduces expression of an
MTTGS gene or the activity of an MTTGS polypeptide by at
least about 10, preferably about 50, more preferably about 75,
90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of
expression of an MTTGS gene or the activity of an MTTGS
polypeptide can be assessed using methods well known in the
art, such as hybridization of nucleotide probes to MTTGSspecific mRNA, quantitative RT-PCR, immunologic detection of an MTTGS polypeptide, or measurement of MTTGS
activity.
In any of the embodiments described above, any of the
pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic
agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art,
according to conventional pharmaceutical principles. The
combination of therapeutic agents can act synergistically to

effect the treatment or prevention of the various disorders
described above. Using this approach, one may be able to
achieve therapeutic efficacy with lower dosages of each
agent, thus reducing the potential for adverse side effects.
Any of the therapeutic methods described above can be
applied to any subject in need of such therapy.
3. Polypeptides
M. tuberculosis TG storage (MTTGS) polypeptides
according to the invention comprise at least 12, 15, 25, 50, 75,
100, 125, 150, 175, 200, 225, 250 or 265 contiguous amino
acids selected from the amino acid sequence shown in SEQ
ID NO: 2, or a biologically active variant thereof, as defined
below. A MTTGS polypeptide of the invention therefore can
be a portion of an MTTGS protein, a full-length MTTGS
protein, or a fusion protein comprising all or a portion of
MTTGS protein.
3.1 Biologically Active Variants
MTTGS polypeptide variants which are biologically
active, i.e., confer an ability by M. tuberculosis to store and/or
process TG, also are considered MTTGS polypeptides for
purposes of this application. Preferably, naturally or nonnaturally occurring MTTGS polypeptide variants have amino
acid sequences which are at least about 55, 60, 65, or 70,
preferably about 75, 80, 85, 90, 96, 96, or 98% identical to the
amino acid sequence shown in SEQ ID NO: 2 or a fragment
thereof. Percent identity between a putative MTTGS
polypeptide variant and an amino acid sequence of SEQ ID
NO: 2 is determined using the Blast2 aligrnnent program
(Blosum62, Expect 10, standard genetic codes).
Variations in percent identity can be due, for example, to
amino acid substitutions, insertions, or deletions. Amino acid
substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted
amino acid has similar structural and/or chemical properties.
Examples of conservative replacements are substitution of a
leucine with an isoleucine or valine, an aspartate with a
glutamate, or a threonine with a serine.
Amino acid insertions or deletions are changes to or within
an amino acid sequence. They typically fall in the range of
about 1 to 5 amino acids. Guidance in determining which
amino acid residues can be substituted, inserted, or deleted
without abolishing biological or immunological activity of an
MTTGS polypeptide can be found using computer programs
well known in the art, such as DNASTAR software. Whether
an amino acid change results in a biologically active MTTGS
polypeptide can readily be determined by assaying for
MTTGS activity, as described for example, in the specific
Examples, below.
3 .2 Fusion Proteins
In some embodiments of the invention, it is useful to create
fusion proteins. By way of example, fusion proteins are useful
for generating antibodies against MTTGS polypeptide amino
acid sequences and for use in various assay systems. For
example, fusion proteins can be used to identify proteins
which interact with portions of an MTTGS polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or
phage display systems, can be used for this purpose. Such
methods are well known in the art and also can be used as drug
screens.
A MTTGS polypeptide fusion protein comprises two
polypeptide segments fused together by means of a peptide
bond. For example, the first polypeptide segment can comprise at least 12, 15, 25, 50, 75, 100, 125, 150, 175, 200, 225,
or 250 contiguous amino acids of SEQ ID NO: 2 or of a
biologically active variant, such as those described above.
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The first polypeptide segment also can comprise full-length
MTTGS protein.
The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion
protein construction include galactosidase, glucuronidase,
green fluorescent protein (GFP), autofluorescent proteins,
including blue fluorescent protein (BFP), glutathione-Stransferase (GST), luciferase, horseradish peroxidase (HRP),
and chloramphenicol acetyltransferase (CAT). Additionally,
epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin
(HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD)
fusions, GAL4 DNA binding domain fusions, and herpes
simplex virus (HSY) BPI 6 protein fusions. A fusion protein
also can be engineered to contain a cleavage site located
between the MTTGS polypeptide-encoding sequence and the
heterologous protein sequence, so that the MTTGS polypeptide can be cleaved and purified away from the heterologous
moiety.
Many kits for constructing fusion proteins are available
from companies such as Promega Corporation (Madison,
Wis.), Stratagene (La Jolla, Calif.), CLONTECH (Mountain
View, Calif.), Santa Cruz Biotechnology (Santa Cruz, Calif.),
MBL International Corporation (MIC; Watertown, Mass.),
and Quantum Biotechnologies (Montreal, Canada; 1-888DNA-KITS).
3.3 Obtaining Polypeptides
MTTGS polypeptides can be obtained, for example, by
purification of polypeptides from M. tuberculosis, expressed
by MTTGs polynucleotide(s) and other appropriate methods
as will be appreciated by those skilled in the art in view of the
teachings herein.
MTTGS polypeptides can be purified from any cell which
expresses the enzyme, including host cells which have been
transfected with MTTGS enzyme expression constructs. A
purified MTTGS enzyme polypeptide is separated from other
compounds which normally associate with the MTTGS
enzyme polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art.
Such methods include, but are not limited to, size exclusion
chromatography, ammonium sulfate fractionation, ion
exchange chromatography, affinity chromatography, and preparative gel electrophoresis. A preparation of purified
MTTGS polypeptides is at least 80% pure; preferably, the
preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such
as SDS-polyacrylamide gel electrophoresis.
4. Polynucleotides
An MTTGS polynucleotide can be single- or doublestranded and comprises a coding sequence or the complement
of a coding sequence for an MTTGS polypeptide. A coding
sequence for MTTGS polypeptide of SEQ ID NO: 2 is shown
in SEQ ID NO: 1.
Degenerate nucleotide sequences encoding MTTGS
polypeptides, as well as homologous nucleotide sequences
which are at least about 50, 55, 60, 65, 60, preferably about
75, 90, 96, or 98% identical to the nucleotide sequence shown
in SEQ ID NO: 1 also are triaglycerol synthase-like enzyme
polynucleotides. Percent sequence identity between the
sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the PASTA
algorithm, using an affine gap search with a gap open penalty
of -12 and a gap extension penalty of -2. Complementary
DNA (cDNA) molecules, species homologs, and variants of

MTTGS polynucleotides which encode biologically active
MTTGS polypeptides also are MTTGS polynucleotides.
4.1 Identification of Polynucleotide Variants and
Homologs
Variants and homologs of the MTTGS polynucleotides
described above also are MTTGS polynucleotides. Typically,
homologous MTTGS polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known
MTTGS polynucleotides under stringent conditions, as is
known in the art. For example, using the following wash
conditions: 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, pH
7.0), 0.1 % SDS, room temperature twice, 30 minutes each;
then 2xSSC, 0.1 % SDS, 50° C. once, 30 minutes; then
2xSSC, room temperature twice, 10 minutes each homologous sequences can be identified which contain at most about
25-30% basepair mismatches. More preferably, homologous
nucleic acid strands contain 15-25% basepair mismatches,
even more preferably 5-15% basepair mismatches.
Species homologs of the MTTGS polynucleotides disclosed herein also can be identified by making suitable probes
or primers and screening cDNA expression libraries. It is well
known that the Tm of a double-stranded DNA decreases by
1-1.5° C. with every 1% decrease in homology (Bonner et al.,
J. Mo!. Biol. 81, 123 (1973). Variants ofMTTGS polynucleotides or polynucleotides of other species can therefore be
identified by hybridizing a putative homologous MTTGS
polynucleotide with a polynucleotide having a nucleotide
sequence of SEQ ID NO: 1 or the complement thereof to form
a test hybrid. The melting temperature of the test hybrid is
compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.
Nucleotide sequences which hybridize to MTTGS polynucleotides or their complements following stringent hybridization and/or wash conditions also are MTTGS polynucleotides. Stringent wash conditions are well known and
understood in the art and are disclosed, for example, in Sambrook et al., MOLECULAR CLONING: A LABORATORY
MANUAL, 2nd ed., 1989, at pages 9.50-9.51.
Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen
that is approximately 12-20° C. below the calculated T mofthe
hybrid under study. The Tmof a hybrid between an MTTGS
polynucleotide having a nucleotide sequence shown in SEQ
ID NO: 1 or the complement thereof and a polynucleotide
sequence which is at least about 50, preferably about 75, 90,
96, or 98% identical to one of those nucleotide sequences can
be calculated, for example, using the equation of Bolton and
McCarthy, Proc. Natl. Acad. Sci. U.S.A. 48, 1390 (1962):
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where !=the length of the hybrid in basepairs.
Stringent wash conditions include, for example, 4xSSC at
65° C., or 50% formamide, 4xSSC at 42° C., or 0.5xSSC,
0.1 % SDS at 65° C. Highly stringent wash conditions include,
for example, 0.2xSSC at 65° C.
4.2 Preparation of Polynucleotides
A naturally occurring MTTGS polynucleotide can be isolated free of other cellular components such as membrane
components, proteins, and lipids. Polynucleotides can be
made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification
technique, such as the polymerase chain reaction (PCR), or
by using an automatic synthesizer. Methods for isolating
polynucleotides are routine and are known in the art. Any
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such technique for obtaining a polynucleotide can be used to
obtain isolated MTTGS polynucleotides. For example,
restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises MTTGS nucleotide
sequences. Isolated polynucleotides are in preparations
which are free or at least 70, 80, or 90% free of other molecules.
MTTGS DNA molecules can be made with standard
molecular biology techniques, using MTTGS mRNA as a
template. MTTGS DNA molecules can thereafter be replicated using molecular biology techniques known in the art
and disclosed in manuals such as Sambrook et al. (1989). An
amplification technique, such as PCR, can be used to obtain
additional copies of polynucleotides of the invention. The
inventors have successfully demonstrated this approach.
Alternatively, synthetic chemistry techniques can be used
to synthesizes MTTGS polynucleotides. The degeneracy of
the genetic code allows alternate nucleotide sequences to be
synthesized which will encode a MTTGS polypeptide having, for example, an amino acid sequence shown in SEQ ID
NO: 2 or a biologically active variant thereof.
4.3 Expression of Polynucleotides
To express a MTTGS polynucleotide, the polynucleotide
can be inserted into an expression vector which contains the
necessary elements for the transcription and translation of the
inserted coding sequence. Methods which are well known to
those skilled in the art can be used to construct expression
vectors containing sequences encoding MTTGS polypeptides and appropriate transcriptional and translational control
elements. These methods include in vitro recombinant DNA
techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook et al. (1989) and in Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &
Sons, New York, N.Y., 1989.
A variety of expression vector/host systems can be utilized
to contain and express sequences encoding a MTTGS
enzyme polypeptide. These include, but are not limited to,
microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect
cell systems infected with virus expression vectors (e.g.,
baculovirus), plant cell systems transformed with virus
expression vectors (e.g., cauliflower mosaic virus, CaMV;
tobacco mosaic virus, TMV) or with bacterial expression
vectors (e.g., Ti orpBR322 plasmids), or animal cell systems.
The control elements or regulatory sequences are those
nontranslated regions of the vector enhancers, promoters, 5'
and 3' untranslated regions which interact with host cellular
proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on
the vector system and host utilized, any number of suitable
transcription and translation elements, including constitutive
and inducible promoters, can be used. For example, when
cloning in bacterial systems, inducible promoters such as the
hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORTl plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin
promoter can be used in insect cells. Promoters or enhancers
derived from the genomes of plant cells (e.g., heat shock,
RUBISCO, and storage protein genes) or from plant viruses
(e.g., viral promoters or leader sequences) can be cloned into
the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it
is necessary to generate a cell line that contains multiple
copies of a nucleotide sequence encoding an MTTGS

polypeptide, vectors based on SV40 or EBY can be used with
an appropriate selectable marker.
5. Host Cells
According to certain embodiments of the subject invention, an MTTGS polynucleotide will need to be inserted into
a host cell, for expression, processing and/or screening. A
host cell strain can be chosen for its ability to modulate the
expression of the inserted sequences or to process the
expressed MTTGS polypeptide in the desired fashion. Such
modifications of the polypeptide include, but are not limited
to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Posttranslational processing
which cleaves a "prepro" form of the polypeptide also can be
used to facilitate correct insertion, folding and/or function.
Different host cells which have specific cellular machinery
and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and W138), are
available from the American Type Culture Collection (ATCC;
10801 University Boulevard, Manassas, Va. 20110-2209) and
can be chosen to ensure the correct modification and processing of the foreign protein.
Stable expression is preferred for long-term, high yield
production of recombinant proteins. For example, cell lines
which stably express MTTGS polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements
and a selectable marker gene on the same or on a separate
vector. Following the introduction of the vector, cells can be
allowed to grow for 12 days in an enriched medium before
they are switched to a selective medium. The purpose of the
selectable marker is to confer resistance to selection, and its
presence allows growth and recovery of cells which successfully express the introduced MTTGS sequences. Resistant
clones of stably transformed cells can be proliferated using
tissue culture techniques appropriate to the cell type. See, for
example, ANIMAL CELL CULTURE, R. I. Freshney, ed.,
1986.
5 .1 Detecting Expression
A variety of protocols for detecting and measuring the
expression of a MTTGS polypeptide, using either polyclonal
or monoclonal antibodies specific for the polypeptide, are
known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies
reactive to two non-interfering epitopes on a MTTGS
polypeptide can be used, or a competitive binding assay can
be employed. These and other assays are described in Hampton et al., SEROLOGICAL METHODS: A LABORATORY
MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox et
al., J. Exp. Med. 158, 1211-1216, 1983).
5 .2 Expression and Purification of Polypeptides
Host cells transformed with nucleotide sequences encoding MTTGS polypeptide can be cultured under conditions
suitable for the expression and recovery of the protein from
cell culture. The polypeptide produced by a transformed cell
can be secreted or contained intracellularly depending on the
sequence and/or the vector used. As will be understood by
those of skill in the art, expression vectors containing polynucleotides which encode MTTGS polypeptides can be
designed to contain signal sequences which direct secretion
of soluble MTTGS polypeptides through a prokaryotic or
enkaryotic cell membrane or which direct the membrane
insertion of membrane-bound MTTGS polypeptide.
6. Antibodies
Antibodies are referenced herein and various aspects of the
subject invention utilize antibodies specific to MTTGS
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polypeptide(s ). As described above, one example of a therapeutic agent may pertain to an antibody. Any type of antibody
known in the art can be generated to bind specifically to an
epitope of an MTTGS polypeptide. "Antibody" as used
herein includes intact immunoglobulin molecules, as well as
fragments thereof, such as Fab, F(ab') 2 , and Fv, which are
capable of binding an epitope of an MTTGS polypeptide.
Typically, at least 6, 8, 10, or 12 contiguous amino acids are
required to form an epitope. However, epitopes which involve
non-contiguous amino acids may require more, e.g., at least
15, 25, or 50 amino acids.
An antibody which specifically binds to an epitope of an
MTTGS polypeptide can be used therapeutically, as mentioned, as well as in immunochemical assays, such as Western
blots, ELISAs, radioimmunoassays, immunohistochemical
assays, immunoprecipitations, or other immunochemical
assays known in the art. Various immunoassays can be used to
identify antibodies having the desired specificity. Numerous
protocols for competitive binding or immunoradiometric
assays are well known in the art. Such immunoassays typically involve the measurement of complex formation
between an immunogen and an antibody which specifically
binds to the immunogen. Antibodies useful for embodiments
of the subject invention may be polyclonal, but are preferably
monoclonal antibodies.
7. Ribozymes
Ribozymes may be one category oftest compounds potentially useful as therapeutic agents for treatment of TB infection. Ribozymes are RNA molecules with catalytic activity.
See, e.g., Cech, Science 236, 1532-1539; 1987; Cech, Ann.
Rev. Biochem. 59, 543-568; 1990, Cech, Curr. Opin. Struct.
Biol. 2, 605-609; 1992, Couture & Stinchcomb, Trends
Genet. 12, 510-515, 1996. Ribozymes can be used to inhibit
gene function by cleaving an RNA sequence, as is known in
the art (e.g., Haseloff et al., U.S. Pat. No. 5,641,673). The
mechanism of ribozyme action involves sequence-specific
hybridization of the ribozyme molecule to complementary
target RNA, followed by endonucleolytic cleavage.
Examples include engineered hammerhead motif ribozyme
molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.
Accordingly, another aspect of the invention pertains to
using the coding sequence of a MTTGS polynucleotide to
generate ribozymes which will specifically bind to mRNA
transcribed from the MTTGS polynucleotide. Methods of
designing and constructing ribozymes which can cleave other
RNA molecules in trans in a highly sequence specific manner
have been developed and described in the art (see Haseloff et
al. Nature 334, 585-591, 1988). For example, the cleavage
activity of ribozymes can be targeted to specific RNAs by
engineering a discrete "hybridization" region into the
ribozyme. The hybridization region contains a sequence
complementary to the target RNA and thus specifically
hybridizes with the target (see, for example, Gerlach et al., EP
321,201).
Specific ribozyme cleavage sites within a MTTGS RNA
target can be identified by scanning the target molecule for
ribozyme cleavage sites which include the following
sequences: GUA, GUU, and GUC. Once identified, short
RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the
cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of
candidate MTTGS RNA targets also can be evaluated by
testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. Longer
complementary sequences can be used to increase the affinity

of the hybridization sequence for the target. The hybridizing
and cleavage regions of the ribozyme can be integrally related
such that upon hybridizing to the target RNA through the
complementary regions, the catalytic region of the ribozyme
can cleave the target.
Ribozymes can be introduced into cells as part of a DNA
construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium
phosphate precipitation, can be used to introduce a ribozymecontaining DNA construct into cells in which it is desired to
decrease MTTGS expression. Alternatively, if it is desired
that the cells stably retain the DNA construct, the construct
can be supplied on a plasmid and maintained as a separate
element or integrated into the genome of the cells, as is known
in the art. A ribozyme-encoding DNA construct can include
transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional
terminator signal, for controlling transcription of ribozymes
in the cells.
As taught in Haseloff et al., U.S. Pat. No. 5,641,673,
ribozymes can be engineered so that ribozyme expression
will occur in response to factors which induce expression of a
target gene. Ribozymes also can be engineered to provide an
additional level of regulation, so that destruction of mRNA
occurs only when both a ribozyme and a target gene are
induced in the cells.
8. tgsl Deficiency Abolishes TG Accumulation Under
Conditions that Lead to Dormancy-Like State, and that
Complementation Restores TG Accumulation
8.1 Introduction
Tuberculosis (TB), one of the biggest killers among the
infectious diseases, poses a major public health problem
mostly in the developing world with 8 million new TB cases
and 2 million deaths a year. Mycobacterium tuberculosis, the
causative agent of TB, is inhaled by people emanating as
aerosol from active TB patients. Usually only a small fraction
of the people (about 5%) thus infected develop active TB,
while the rest carry latent infection for the rest of their lives
until reactivation of the pathogen occurs upon weakening of
the immune system. Thus, AIDS causes reactivation of the
latent tubercule bacillus leading to rapid bacillary growth and
dissemination resulting in the development of active TB. The
ability of the pathogen to go into a latent/dormant non-replicating state with very low metabolic activity and resistance to
all of the currently available antituberculosis drugs makes TB
eradication an extremely difficult challenge.
The metabolic and physiological state of the dormant
pathogen that allows it to survive inside the host for decades
remains unclear. There is strong evidence that fatty acids are
the energy source to be used by the pathogen for its long term
survival during the persistence phase of infection. In M.
tuberculosis, two genes icl 1 and icl2 encode isocitrate lyase
(ICL)- a key metabolic enzyme involved in fatty acid utilization. It was recently shown that deletion of both icl 1 and icl2,
but not deletion of either one. resulted in complete impairment of intracellular replication in macrophages and rapid
elimination from the mouse lungs. Chemical inhibition of
both ICLl and ICL2 also blocked the growth of M. tuberculosis on fatty acids and in macrophages. However the source
of the fatty acids remains unknown. Recently, the inventors
have shown that M. tuberculosis can synthesize and store
triacylglycerol (TG) as an energy reserve under hypoxia and
NO treatment, the stress conditions that lead to a dormancylike state in culture. Intracellular TG inclusion bodies found
in the pathogen (M. tuberculosis) obtained from organ lesions
and decrease of TG levels by growth of M. Bovis BCG in
macrophages suggest that TG is used as an energy source for
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intracellular growth of the pathogen. The genes that could be
involved in the synthesis of TO in the pathogen were recently
identified. The inventors found 15 members of a novel class of
diacylglycerol acyltransferase genes designated tgs (triacylglycerol synthase) based on homology to such genes identified
in Acinetobacter calcoaceticus. Which, if any of these genes,
encodes the enzyme(s) actually involved in TG synthesis has
not been established. The inventors previously assessed the
degree ofupregulation of the putative tgs genes upon induction of dormancy-like conditions in culture. The inventors
also determined the enzyme activity of the mycobacterial tgs
products expressed in Escherichia coli. Based on these
results, tgs 1 appeared to have the highest potential to contribute to TG accumulation. In this report, it is shown that tgsl
deficiency abolishes TG accumulation under conditions that
lead to dormancy-like state, and that complementation
restores TG accumulation. It is also shown that TGSl
expressed in E. coli, preferentially uses C 26 fatty acyl-CoA
for TG synthesis and that C 26 fatty acid, which is known to be
produced by the fatty acid synthase of M. tuberculosis, found
to be a major long chain fatty acid in the TG accumulated
under conditions that lead to a dormancy-like state. This
enzyme is highly active over a wide range of pH including the
acidic conditions expected in the granuloma.
8.2 Materials and Methods
Bacterial strains, Growth media and Chemicals. M. tuberculosis H37Rv (ATCC 25618), tgsl mutant and complemented strain were grown in Middlebrook 7H9 (Difeo,
Detroit, Mich.), in Dubas-Tween-albumin medium broth
(Difeo, Detroit, Mich.) and Sauton medium as previously
described (6). Escherichia coli DH5a and HB101 strains
(Life Technologies, Gaithersburg, Md.) were used for cloning
and propagation of plasmids and phasmids. For selection of
transformants, E. coli was grown in Luria-Bertani (LB) broth
or agar. M. smegmatis mc 2 155 was grown in liquid LB
medium with 0.5% Tween 80 for competent cell preparation
and in Middlebrook 7H9 broth with 0.05% Tween 80 for
transduction. When required, antibiotics were added to the
culture media at the following concentration: ampicillin, 100
µg/ml for E.coli; hygromycin B, 150 µg/ml for E.coli or 75
µg/ml for M. tuberculosis; kanamycin, 50 µg/ml for E. coli or
20 µg/ml for M. tuberculosis. The NO donor (spermine NONOate) and its reference compound, spermine tetrahydrochloride were purchased from Alexis Corporation. Other chemicals and antibiotics were from Sigma Chemical Co. and
Fisher Scientific. DNA restriction and modifying enzymes
were obtained from New England Bio-labs (Beverly, Mass.).
Growth Conditions for M. tuberculosis. To mimic a dormancy-like state in culture, in vitro stress conditions such as
hypoxia, NO treatment, low pH and static growth were used.
For hypoxia and NO treatment, experiments were done as
previously described (6). Resistance to isoniazid (0.4 µg/ml)
and sensitivity to metronidazole (12 µg/ml) of hypoxic cultures were also tested ( 6). For low pH growth, M. tuberculosis
cells were initially grown in Middlebrook 7H9 media until
OD 600 of0.6-0.8, and the cells were washed and suspended in
Middlebrook 7H9 media, pH 5.0 and grown for three weeks
in a roller bottle at 37° C. For growth under static condition,
M. tuberculosis cells were grown for 2 weeks in Middlebrook
7H9 media until OD 600 of1.6 and then the culture was kept
standing for 1 week at 3 7° C. Cells collected at different time
periods were used for RNA isolation and TG analysis.
Generation of tgsl Disrupted Mutant of M. tuberculosis.
The general strategy used for gene disruption with the specialized transducing phage system was similar to that used
previously (1, 28). tgs 1 was disrupted by allelic exchange via
specialized transduction using conditionally replicating

mycobacteriophage phAE87. The disrupted copy of the gene
was constructed by PCR amplification of the 5'-flanking and
the 3'-flanking regions of the geneusingM. tuberculosis DNA
as a template and primer pairs introducing BspHI and Pstl
sites and XhoI and BspHI sites at the ends of the products,
respectively (Table 1). Both products were then sequentially
inserted on either side of the hygromycin resistance gene
(hyg) cloned in vector p UC 19. The 5'-flanking region consists
of the first 10 bp oftgs 1and784 bp sequence upstream of the
gene. The 3'-flanking region contains the last 122 bp oftgsl
open reading frame (orf) and 667 bp downstream sequence.
The disrupted copy of the gene was released by BspHI digestion cloned into pYUB572 which contains a bacteriophage
lambda cos site and a Pacl site. The recombinant cosmid was
digested with Pacl, ligated into the Pacl site of phAE87 and
the resultant recombinant phage was used to transduce wild
type M. tuberculosis. Individual hygromycin resistant colonies were analyzed by PCR and Southern blot analysis to
identify clones in which allelic exchange had occurred at the
tgsl locus. Several tgsl mutants were screened by PCRanalysis using specific primers located inside the deleted fragment
of the gene (llF and llR) shown in Table 1. The allelic
exchange by double cross-over was confirmed with two sets
of primers, each representing a hyg primer (primers Hl and
H2) and a primer (primers E and F) in the mycobacterial
genome outside the gene sequence used for making the disruption construct (FIG. lA).
Complementation of M. tuberculosis tgsl Mutant. For
complementation experiments, tgsl coding sequence was
amplified from genomic M. tuberculosis H37Rv DNA using
Pfu Turbo Hotstart DNA Polymerase (Stratagene ), and primers that introduced a Kpnl site at both ends. The PCR product
was cloned into pCR-Blunt II-TOPO (Invitrogen). After
sequencing to confirm the absence of any mutations, the
insert was excised from this vector by KpnI digestion and
subcloned into Kpnl-digested replicative shuttle vector
pMIP12 for expression under the pBlaF* promoter (18). The
construct was electroporated into the tgs 1 disrupted mutant
and transformants were selected on 7Hl 1 plates with both
kanamycin and hygromycin. Isolated colonies from the plates
were checked for the expression of tgsl by RT-PCR using
primers shown in Table 1. RNA isolation and RT-PCR analysis were done as described previously (6).
Genomic DNA Isolation and Southern blotting. M. tuberculosis H37Rv genomic DNA was isolated by the GTC
method using guanidine thiocyanate, Tris-HCl, Sarcosyl
solution (7). DNA samples were digested with EcoRI and
EcoRI/BamHI restriction enzymes, subjected to 1% agarose
gel electrophoresis, transferred to Nylon membranes (Nytran
Plus, Schleicher and Schnell, Keen, N.H.) and hybridized
with [a- 32 P]dCTP labeled probes using the random prime
labeling system, rediprime II (Amersham Pharmacia Biotech,
UK).
TG Analysis. M. tuberculosis wild type, tgsl mutant and
complemented strain of tgsl cells were subjected to the
desired stress and at defined experimental time points, cells
were recovered by centrifugation, autoclaved and subjected
to lipid extraction in chloroform:methanol (2:1, v/v) (28). In
a separate set of hypoxia experiment, aliquots of the culture
from M. tuberculosis wild type and tgsl mutant taken at
various time points were incubated with 50 µM oleic acid in
0.5% BSA solution and after 6 h of incubation, lipids were
extracted for TG analysis. Total extracted lipids were separated by Silica G thin-layer chromatography (TLC) using
n-hexane:diethylether (9:1, v/v) as solvent system. Dichromate/sulphuric acid charring of TLC plates was used to detect
lipids. The charred TLC plates were also scanned for quanti-
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fication ofTG accumulation using theA!phaimager 2200 Gel
Doc system (Alphainnotech). Fatty acid methyl esters were
prepared from TG by transesterification with 14% BF 3 in
methanol and analyzed by gas chromatography (GC) using
flame ionization detector response; the GC conditions for
fatty acid methyl esters were the same as previously described
(28 ). All stress growth experiments were repeated at least
three times, and similar patterns were seen in all cases. Since
details such as cell density were not absolutely identical in all
repetitions, the average values and the results from a typical
experiment are shown.
Enzyme Activity ofTGSl expressed inE. coli. TGSl was
expressed in E. coli grown in Dual Media (Zymo Research,
CA) for 12 hat 37° C. and total cell lysates were assayed for
TGS activity. The assays were performed in 0.1 M citratephosphate buffer pH 6.5 containing 1 mg BSA, 10 mM
MgCl 2 , 14.5 µM [1 4 C]diolein (specific activity 55 Ci/mo!,
American Radiolabeled Chemicals), 500 µM diolein, indicated concentrations of oleoyl (C 18 , 1 )-CoA or hexacosanoyl
(C 2 ,0 )-CoA and 100-200 µg of protein in a total volume of250
µI for 2 hat 37° C. The pH dependence ofTGS activity was
determined by pre-incubating the total cell lysate containing
the expressed TGSl protein in appropriate buffer prior to
assay using oleoyl-CoA as a model substrate. Following the
assay, the reaction mixture was extracted and the TG product
was quantified as described before (6).
8.3 Results
Disruption oftgsl inM. tuberculosis and complementation
of the disrupted mutant. On the basis of the enzymatic activities of expressed tgs gene products and the level of their
induction as the pathogen entered a dormancy-like conditions, tgsl appeared to be a prime candidate for involvement
in TG synthesis (6). To test this possibility, the inventors
generated a tgsl disrupted mutant of M. tuberculosis. tgsl
was disrupted by allelic exchange via specialized transduction using conditionally replicating mycobacteriophage
phAE87 (1). To prepare the tgsl disruption construct a 1275
bp out of the total 1392 bp tgsl orf was replaced with the
hygromycin-resistance gene and was used as substrate for
allelic exchange by double crossover (FIG. lA). PCR screening of the hygromycin-resistant transductants with a set of
primers (li.F and li.R) specific for the deleted segment identified several mutants that failed to amplify the 662-bp
expected fragment (data not shown). Disruption oftgsl by
homologous recombination was confirmed by further PCR
analysis of the flanking regions (primer pairs E/Hl, H2/F)
which yielded the expected size products. Southern blot
analysis of M. tuberculosis wild type and three tgsl mutants
is shown in FIG. lB. Genomic DNA from M. tuberculosis
digested with EcoRI and BamHI-EcoRI showed a 5.2 kb and
a 2.5 kb hybridization band, respectively when the 5'-flanking
region of the construct was used as the probe. DNA from the
mutants, under the same conditions showed 1. 7 kb band from
both digestions, due to the presence of EcoRI site in the hyg
gene sequence and absence ofBamHI site. RT-PCR analysis
showed that the mutant did not produce any tgsl transcript
(FIG. lC).
The inventors used a replicative shuttle vector, pMIP12 to
complement the disrupted mutant by expressing the tgs 1 orf
under the control of the ~-lactamase promoter (pblaF*) of M.
fortuitum, one of the strongest mycobacterial promoters (18).
After electroporation of the expression construct into the tgs
1 disrupted mutant, transformants were selected on 7Hl 1
plates supplemented with both kanamycin and hygromycin.
Isolated colonies were checked for the restored expression of
tgs 1. RT-PCR analysis of the complemented strain showed
that tgsl was expressed in it (FIG. lC).

TG analysis of M. tuberculosis, tgsl mutant and complemented mutant under hypoxia. Previously, the inventors have
shown that M. tuberculosis accumulates TG under hypoxia, a
condition which induces a dormancy-like state in culture (6).
To test whether tgsl deficiency affected the ability to accumulate TG under such conditions, the inventors cultured the
cells under hypoxia. The samples from both wild type and
tgsl mutant were collected at 0, 6, 11 and 16 days and
extracted lipids were separated by TLC and subjected to
dichromate/sulfuric acid charring to visualize TG. tgs 1
mutant showed no detectable level of TG at any time points
under hypoxic growth condition, whereas wild type started
accumulating TG from day 6 and accumulation of TG was
maximum at day 16 (FIG. 2A). Lipids were isolated from the
silica gel region corresponding to TG and fatty acid analysis
was done by GC. This analysis showed that TG from wild
type contained all fatty acids ranging from C 1 cC 30 with C 26
as the major fatty acid among the longer chain fatty acids,
whereas C 26 fatty acid in tgs 1 mutant was virtually absent
(FIG. 3). To determine whether TG accumulation could be
restored in the tgsl mutant by providing exogenous fatty
acids, the inventors added oleic acid as a BSA complex at
days 6, 11 and 16 in both wild type and tgs 1 mutant cell
cultures. Charring of lipids extracted from these cultures
showed that tgsl mutant at day 11 and 16 contained drastically reduced level of TG when compared to the wild type
(FIG. 2B). Even the trace amounts ofTG present in the tgsl
mutant contained small amounts of the fatty acids present in
the TG in the wild type but C 26 was absent (data not shown).
The small amount ofTG produced by the oleic acid supplemented cultures oftgsl mutant containedoleic acid as a major
component and some C 16 to C 24 fatty acids in similar proportions as found in the wild type but C 26 was barely detectable
(data not shown).
In a separate set of experiments, the inventors also subjected the complemented strain of tgsl mutant to the same
hypoxic condition to see ifthe complemented tgsl strain can
restore TG accumulation. Cultures of wild type, tgsl mutant
and complemented tgs 1 strain were grown under hypoxia for
16 days and the lipids extracted from the cells were separated
by TLC, and the plates were subjected to dichromate/sulphuric acid charring. The results showed that tgsl mutant was
unable to accumulate TG, whereas its complemented strain
accumulated TG just as the wild type (FIG. 4). TG isolated
from both wild type and complemented strain showed a similar fatty acid profile with C 26 as the major fatty acid among the
longer chain fatty acids, whereas C 26 fatty acid was virtually
absent in tgsl mutant (FIG. 3). Acy! chain-length preference
and pH optimum of recombinant TGSl. The fatty acid analysis of the TG produced by the wild type and tgsl mutant
suggested that TGSl may prefer C 26 fatty acyl-CoA as the
substrate. To test for this possibility, the inventors expressed
TGS 1 in E. coli and assayed the TGS activity in the total cell
lysate using both C 18 , 1 and C 26 ,0 -CoA as substrates. Results
clearly showed that TGSl has a preference for C 26 ,0 -CoA
over C 18 ,0 -CoA (FIG. SA). The Km values for C 26 ,0 -CoA and
C 18 , 1 -CoA were calculated to be 306 µMand 540 µM, respectively from linear double-reciprocal plots. The respective
V max values for C 26 ,0 -CoA and C 18 , 1 -CoA were calculated to
be 2.4 nmol/mg/min and 1.1 nmol/mg/min. The enzyme displayed maximal activity at a wide range of pH from pH 4.5 to
pH 7.5 (FIG. SB). Role oftgsl in TG synthesis under acidic
and static growth conditions and upon NO treatment. Besides
hypoxic stress, dormant bacilli are also believed to encounter
other stress factors such as acidic pH in caseous granuloma,
slow growth under static phase and NO production inside the
host macrophages (4, 9, 20, 25). Therefore, it was tested
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whether tgsI mutant is able to accumulate TG under such
stress conditions that may share features with the dormant
state. M. tuberculosis wild type, tgs I mutant and tgsIcomplement strain were grown under acidic stress condition
and TG accumulation was analyzed. After three weeks of
growth in acidic media the wild type accumulated TG but in
tgs I mutant TG was not detected, whereas its complemented
strain accumulated a level ofTG similar to that found in the
wild type (FIG. 6A). Fatty acid analysis of the TG accumulated under acidic condition showed that the major fatty acids
were C 1 cC 28 with C 26 as the major component among the
longer fatty acids. tgsI mutant showed no detectable level of
C 26 fatty acid even in the trace amount ofTG that was found.
Complemented tgsI mutant showed a TG fatty acid profile
identical to that in the wild type (data not shown).
M. tuberculosis culture grown under static conditions is
known to share features with those of non-replicative latent
state (9). To test whether TG accumulates under such a condition and to ascertain whethertgs I product is involved in TG
synthesis under such a condition, it was tested wild type, tgs I
mutant and complemented mutant. Cell cultures grown for
two weeks in Middlebrook 7H9 media in a roller incubator,
was allowed to settle and were further incubated for I week as
standing cultures. Total lipids were extracted from these cultures and analyzed by TLC. Dichromate/sulphuric acid charring results showed that tgsI mutant lost the ability to accumulate TG. The complemented strain accumulated TG to a
level similar to the one observed in wild type (FIG. 6B). Fatty
acid analysis of the TG from both wild type and complemented mutant strain showed a similar fatty acids profile with
C 16 and C 18 being the major ones along with very low level of
longer chain fatty acids (C 20 -C 26 ), whereas in tgs I mutant
that showed the same proportion of smaller chain fatty acids,
C 26 was not even detectable (data not shown).
Treatment of M. tuberculosis with NO is known to trigger
induction of the hypoxia regulon (21, 30) and cause accumulation ofTG (6). To test for the role oftgsI in TG accumulati on, tgs I mutant and its complemented strain were subjected
to NO treatment. After 6 hr of NO treatment, cells were
harvested for total lipid extraction. The lipids were separated
by TLC, and the dichromate/sulphuric acid charring of the
TLC plate showed that the TG level in tgsI mutant was much
less (30%) compared to the wild type, whereas its complemented strain accumulated TG to a level comparable to that
found in the wild-type (FIG. 6C). Fatty acid analysis ofTG
isolated from both wild type and tgsI-complemented strain
showed C 16 -C 28 fatty acids with C 26 as a major component;
however in tgs I mutant, the level of C 26 fatty acid was
drastically reduced (data not shown).
RT-PCR analyses of tgs transcript levels under various
growth conditions. Induction levels of I 5 tgs genes were
assessed by semiquantitative RT-PCR analyses of mRNA
isolated from cells of wild type, tgsI mutant and tgs I-complemented strains grown under different stress conditions. Transcript levels oftgs genes are expressed as the fraction of23S
rRNA transcript. The tgs I transcript was completely absent in
the tgsI mutant and it was induced in wild type and tgsIcomplemented strains under all the stress conditions, as
expected. Transcript levels of other tgs genes under hypoxic,
static and acidic growth condition were similar in all the three
strains (data not shown). In NO-treated cells oftgsI mutant
transcript levels of Rv337I, RvI 760, Rv2285 and RvI425
were slightly more than the wild type and tgs I-complemented
strain (FIG. 7).
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All patents, patent applications, publications, texts and
references discussed or cited herein are incorporated by reference to the extent not inconsistent with the teachings herein.
In addition, all terms not specifically defined are first taken to
have the meaning given through usage in this disclosure, and
if no such meaning is inferable, their normal meaning. Where
a limitation is described but not given a specific term, a term
corresponding to such limitation may be taken from any
references, patents, applications, and other documents cited
herein.
The present invention is not to be limited in scope by the
specific embodiments described herein. Indeed, various
modifications of the invention in addition to those described
herein will become apparent to those skilled in the art from
the foregoing description. Such modifications are intended to
fall within the scope of the appended claims. Thus, for the
above variations and in other regards, it should be understood
that the examples and embodiments described herein are for
illustrative purposes only and that various modifications or
changes in light thereof will be suggested to persons skilled in
the art and are to be included within the spirit and purview of
this application and the scope of the appended claims.

TABLE 1

35

Set of primers used for making tgsl disruption

construct in M.

tuberculosis (SEQ ID NOS 4-17,

respectively in order of appearance)

40

Primer pairs used to generate 5'- and 3'-

flanks of tgsl genes
5' flank

A-5'-tcatgatcttggcgatctccagc-3'

B-5'-ctgcagggtgattcatggtcagc-3'
45

3' flank

C-5'-ctcgagacgtggtagcagatgcc-3'
D-5'-tcatgatacttcccgcactgccc-3'

Primer pair inside the deleted segment
~F-5'-ttatcgtcgctc

50

gctcaa cgcc-3'

~R-5'-tttccgtaatcgcggcaagcgc-3'

Primer pair used for genomic flanks
5'

flank

55

E,-5'-cggcattgatcggtgcccaaccc-3'

Hl-5'-tgaggcgatggtggtgtcgatgct-3'
3' flank

H2-5'-ggaactggcgcagttcctctgggg-3'
F-5'-tcacgcccaaactccaacacaccg-3'
Primer pair used for RT-PCR

60

tgsl

23S rRNA
65

F-5'-tgggtcgtcgacatgggtggcgag-3'
R-5'-cgtgctaagtcccgccgcgtc-3'
F-5'-gtggcgtgttctggacccgaagcg-3'
R-5'-gtccatcgactacgcctgtcggcc-3'
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 17
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 1392
TYPE, DNA
ORGANISM: Mycobacterium tuberculosis

<400> SEQUENCE, 1
atgaatcacc taacgacact tgacgccggg tttctcaagg cagaagacgt ggatcggcac

60

gtgagtctgg caatcggcgc tctggcggtc atcgaggggc cggctcccga tcaggaagcc

120

ttcttatcgt cgctcgctca acgcctacgt ccctgtaccc ggttcgggca gcggttacgc

180

ctgcgcccgt tcgacctcgg tgcacccaaa tgggtggacg atcccgactt cgatcttggc

240

cgtcatgtgt ggcgcatcgc cttgccgcgg cctggcaacg aagaccagtt attcgagctg

300

atcgccgatc tgatggcgcg tcgtttggac cggggtcgac cgctgtggga ggtctgggtc

360

atcgaaggcc tggcggacag caagtgggcg atcctgacca aactgcacca ctgcatggcc

420

gacggaatcg cggcgactca cctgctagct gggctctccg atgaaagtat gagcgacagc

480

ttcgcgagca acatccacac gaccatgcag tcgcaatccg catctgtgcg gcggggtgga

540

ttccgtgtca atccaagcga ggcgttgacc gcgtcgaccg ccgtgatggc aggcatcgtt

600

cgcgcggcca agggtgccag tgagatcgcg gccggcgtgc taagtcccgc cgcgtcgtcg

660

ttgaacgggc cgatcagtga tttgcgtcgc tacagcgcag caaaggtccc tctcgccgac

720

gtcgaacagg tgtgccggaa attcgacgtc accatcaatg atgttgcgct tgccgcgatt

780

acggaaagct accgcaacgt cctcatccag cggggtgagc ggcctaggtt tgattcgctg

840

cgtacgctag tgccggtctc gacgcgttcc aacagcgctt tgagcaagac cgataaccgt

900

gtttcgttaa tgctgcccaa cctgccggtg gatcaagaga acccgctgca gcggctgcgg

960

atcgtgcact cgcggctgac tcgggccaag gcggggggac agagacaatt cggaaatact

1020

ttgatggcga ttgccaaccg ccttccgttc cccatgaccg catgggcggt cgggctgttg

1080

atgcggctgc cgcagcgtgg tgttgtcacc gtggcgacaa atgtgccggg tccacgacgg

1140

ccgctgcaga ttatgggcag acgggtgctt gacctatacc cggtttcgcc gatcgcgatg

1200

caactgcgca ccagtgtcgc gatgctcagc tacgccgacg acctgtactt cgggatcctg

1260

gccgactacg acgtggtagc agatgccggc cagctggcgc gaggaattga agacgccgtc

1320

gcacggctgg tggcgatcag taagcggcgc aaggtgactc gcaggcgcgg agcgctatcg

1380

ctggttgtgt ga

1392

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 463
TYPE, PRT
ORGANISM: Mycobacterium tuberculosis

<400> SEQUENCE, 2
Met Asn His Leu Thr Thr Leu Asp Ala Gly Phe Leu Lys Ala Glu Asp
1
5
10
15
Val Asp Arg His Val Ser Leu Ala Ile Gly Ala Leu Ala Val Ile Glu
20
25
30
Gly Pro Ala Pro Asp Gln Glu Ala Phe Leu Ser Ser Leu Ala Gln Arg
35
40
45
Leu Arg Pro Cys Thr Arg Phe Gly Gln Arg Leu Arg Leu Arg Pro Phe
50
55
60
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28
-continued

Asp Leu Gly Ala Pro Lys Trp Val Asp Asp Pro Asp Phe Asp Leu Gly
65
70
75
80
Arg His Val Trp Arg Ile Ala Leu Pro Arg Pro Gly Asn Glu Asp Gln
85
90
95
Leu Phe Glu Leu Ile Ala Asp Leu Met Ala Arg Arg Leu Asp Arg Gly
100
105
110
Arg Pro Leu Trp Glu Val Trp Val Ile Glu Gly Leu Ala Asp Ser Lys
115
120
125
Trp Ala Ile Leu Thr Lys Leu His His Cys Met Ala Asp Gly Ile Ala
130
135
140
Ala Thr His Leu Leu Ala Gly Leu Ser Asp Glu Ser Met Ser Asp Ser
145
150
155
160
Phe Ala Ser Asn Ile His Thr Thr Met Gln Ser Gln Ser Ala Ser Val
165
170
175
Arg Arg Gly Gly Phe Arg Val Asn Pro Ser Glu Ala Leu Thr Ala Ser
180
185
190
Thr Ala Val Met Ala Gly Ile Val Arg Ala Ala Lys Gly Ala Ser Glu
195
200
205
Ile Ala Ala Gly Val Leu Ser Pro Ala Ala Ser Ser Leu Asn Gly Pro
210
215
220
Ile Ser Asp Leu Arg Arg Tyr Ser Ala Ala Lys Val Pro Leu Ala Asp
225
230
235
240
Val Glu Gln Val Cys Arg Lys Phe Asp Val Thr Ile Asn Asp Val Ala
245
250
255
Leu Ala Ala Ile Thr Glu Ser Tyr Arg Asn Val Leu Ile Gln Arg Gly
260
265
270
Glu Arg Pro Arg Phe Asp Ser Leu Arg Thr Leu Val Pro Val Ser Thr
275
280
285
Arg Ser Asn Ser Ala Leu Ser Lys Thr Asp Asn Arg Val Ser Leu Met
290
295
300
Leu Pro Asn Leu Pro Val Asp Gln Glu Asn Pro Leu Gln Arg Leu Arg
305
310
315
320
Ile Val His Ser Arg Leu Thr Arg Ala Lys Ala Gly Gly Gln Arg Gln
325
330
335
Phe Gly Asn Thr Leu Met Ala Ile Ala Asn Arg Leu Pro Phe Pro Met
340
345
350
Thr Ala Trp Ala Val Gly Leu Leu Met Arg Leu Pro Gln Arg Gly Val
355
360
365
Val Thr Val Ala Thr Asn Val Pro Gly Pro Arg Arg Pro Leu Gln Ile
370
375
380
Met Gly Arg Arg Val Leu Asp Leu Tyr Pro Val Ser Pro Ile Ala Met
385
390
395
400
Gln Leu Arg Thr Ser Val Ala Met Leu Ser Tyr Ala Asp Asp Leu Tyr
405
410
415
Phe Gly Ile Leu Ala Asp Tyr Asp Val Val Ala Asp Ala Gly Gln Leu
420
425
430
Ala Arg Gly Ile Glu Asp Ala Val Ala Arg Leu Val Ala Ile Ser Lys
435
440
445
Arg Arg Lys Val Thr Arg Arg Arg Gly Ala Leu Ser Leu Val Val
450
455
460

<210> SEQ ID NO 3
<211> LENGTH, 110
<212> TYPE, PRT
<213> ORGANISM: Mycobacterium tuberculosis

US 7,993,658 B2
29

30
-continued

<400> SEQUENCE, 3
Met Val Gln Gly Arg Thr Val Leu Phe Arg Thr Ala Glu Gly Ala Lys
1
5
10
15
Leu Phe Ser Ala Val Ala Lys Cys Ala Val Ala Phe Glu Ala Asp Asp
20
25
30
His Asn Val Ala Glu Gly Trp Ser Val Ile Val Lys Val Arg Ala Gln
35
40
45
Val Leu Thr Thr Asp Ala Gly Val Arg Glu Ala Glu Arg Ala Gln Leu
50
55
60
Leu Pro Trp Thr Ala Thr Leu Lys Arg His Cys Val Arg Val Ile Pro
65
70
75
80
Trp Glu Ile Thr Gly Arg His Phe Arg Phe Gly Pro Glu Pro Asp Arg
85
90
95
Ser Gln Thr Phe Ala Cys Glu Ala Ser Ser His Asn Gln Arg
100
105
110

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 4
tcatgatctt ggcgatctcc age

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 5
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 5
ctgcagggtg attcatggtc age

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 6
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE,
ctcgagacgt ggtagcagat gee

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 7
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 7
tcatgatact tcccgcactg ccc

<210> SEQ ID NO 8
<211> LENGTH, 22
<212> TYPE, DNA

23
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32
-continued

<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer
<400> SEQUENCE, 8
ttatcgtcgc tcgctcaacg cc

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 9
LENGTH, 22
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 9
tttccgtaat cgcggcaagc gc

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 10
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 10
cggcattgat cggtgcccaa ccc

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 11
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 11
tgaggcgatg gtggtgtcga tgct

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 12
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 12
ggaactggcg cagttcctct gggg

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 13
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 13
tcacgcccaa actccaacac accg

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 14
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,

24
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33
-continued
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer
<400> SEQUENCE, 14
tgggtcgtcg acatgggtgg cgag

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 15
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 15
cgtgctaagt cccgccgcgt c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 16
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 16
gtggcgtgtt ctggacccga agcg

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 17
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 17
24

gtccatcgac tacgcctgtc ggcc
40

What is claimed is:
1. An agent which regulates the activity of a Mycobacterium tuberculosis triacylglycerol storage (MTTGS) polypep-

tide, said agent being an RNA molecule, an antisense oligonucleotide, or a ribozyme that targets a nucleic acid sequence
encoding SEQ ID NO. 2.

* * * * *

